Akums launches generic formulation to treat migraine
时间:2024-06-26 11:56:12 阅读(143)
Akums Drugs & Pharmaceuticals Ltd., a contract manufacturing pharmaceutical company, on Friday announced that it has launched the Lasmiditan tablet which is prescribed to treat migraine. This medication has received approvals from the Drug Controller General of India (DCGI) and the United States Food and Drug Administration (USFDA).
It is the generic formulation of Eli Lilly’s REYVOW which is indicated for treatment of acute migraine.
In a 2019 report, it was revealed that headache disorders, including both migraines and tension-type headaches, have emerged as the most prevalent neurological conditions in India, affecting an astonishing 488 million individuals.
The International Headache Society (IHS) outlines criteria for diagnosing migraine, including specific characteristics and associated symptoms observed in at least five attacks. Two main subtypes, migraine without aura and migraine with aura, present distinct features, with the latter involving focal neurological symptoms preceding or accompanying the headache.
“Migraine poses a significant global impact. According to a 2019 report, headache disorders, encompassing migraine and tension-type headaches, emerged as the most widespread neurological conditions in India, impacting a staggering 488 million individuals. Despite this substantial prevalence and the resulting disability, migraine awareness among patients remains inadequate. Compounded by frequent misdiagnosis as other headache disorders, these factors contribute to an increased burden associated with migraine. In light of this, Akums aims to provide a solution for managing this condition with the introduction of the Lasmiditan tablet,” Sanjeev Jain, Joint Managing Director, Akums Drugs & Pharmaceuticals Ltd., said.
猜你喜欢
- Agilus Diagnostics files draft papers with Sebi to raise funds via IPO
- Nifty tops 17300, Sensex surges 1100 pts, here’s what is fuelling the rally; should you buy or sell-
- AILET BA LLB 2024 provisional allotment 1 result out on nationallawuniversitydelhi
- Nifty to trade in 16,300-16,900 range, Bank Nifty may top 37,000 this week; TCS, Britannia stocks in focus
- North Korea’s Kim vows to launch 3 more spy satellites and produce more nuclear materials in 2024
- Nifty, Bank Nifty outlook- Buy on dips in Nifty quality cos, Bank Nifty to trade in range; buy Reliance, SBI
- Antfin may sell 3
- Aether Industries IPO closes today, grey market premium falls; Should you subscribe-
- Nifty to rise above 17,000 or extend losses- Check 8 key things to know before share market opening bell